Physician profile
Michael D Yoslov
NPI 1780653956
$79,094.73
in general payments reported to CMS, 2019-2025
38 companies · $6,715 in 2025
The $6,715 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $333 · 2021: $1,321 · 2022: $24K · 2023: $28K · 2024: $18K · 2025: $6,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $6,875 · Travel and Lodging: $1,184 · Education: $30.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,587.00 |
| Food and Beverage | $6,875.42 |
| Travel and Lodging | $1,183.83 |
| Education | $30.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71,575.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,299.26 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $1,083.84 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $779.03 | 2019-2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $440.94 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $423.72 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $350.78 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $312.64 | 2019-2025 | Krystexxa, Tavneos |
| Daiichi Sankyo INC. | $281.59 | 2021-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $269.98 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $186.97 | 2022-2024 | Lupkynis |
| Genzyme Corporation | $185.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $171.54 | 2022-2025 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $168.84 | 2023-2025 | |
| Horizon Therapeutics Plc | $163.12 | 2020-2023 | Krystexxa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yoslov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.